FDA's "Act Now" Philosophy Has Drawbacks For Industry - CHPA Exec
FDA's current speed in taking action sometimes sacrifices fair treatment of industry and can fail to allow for logistical realities, according to OTC stakeholders
More from Archive
More from Pink Sheet
The European Medicines Agency has revised the sponsor handbook for the Clinical Trials Information System, bringing together guidance that was previously scattered across multiple platforms and documents to help sponsors navigate the trial process more efficiently.
The long-time industry executive led several drug approvals but may have a lot to learn about the intimate details of application review and the Center for Drug Evaluation and Research.
The US FDA's Psychopharmacology Advisory Committee emphasized high standards over regulatory flexibility while turning down Otsuka's brexpiprazole plus serotonin for post-traumatic stress disorder based on conflicting Phase III trials and post-hoc Phase II analyses.